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Background: Postprandial elevation of triglyceride-rich lipoproteins impairs endothelial function, which can initiate
atherosclerosis. We investigated the effects of bezafibrate on postprandial endothelial dysfunction and lipid profiles
in patients with metabolic syndrome.
Methods: Ten patients with metabolic syndrome were treated with 400 mg/day bezafibrate or untreated for
4 weeks in a randomized crossover study. Brachial artery flow-mediated dilation (FMD) and lipid profiles were
assessed during fasting and after consumption of a standardized snack. Serum triglyceride and cholesterol contents
of lipoprotein fractions were analyzed by high-performance liquid chromatography.
Results: Postprandial FMD decreased significantly and reached its lowest value 4 h after the cookie test in both
the bezafibrate and control groups, but the relative change in FMD from baseline to minimum in the bezafibrate
group was significantly smaller than that in the control group (−29.0 ± 5.9 vs. −42.9 ± 6.2 %, p = 0.04). Bezafibrate
significantly suppressed postprandial elevation of triglyceride (incremental area under the curve (AUC): 544 ± 65 vs.
1158 ± 283 mg h/dl, p = 0.02) and remnant lipoprotein cholesterol (incremental AUC: 27.9 ± 3.5 vs. 72.3 ±
14.1 mg h/dl, p < 0.01). High-performance liquid chromatography analysis revealed that postprandial triglyceride
content of the chylomicron and very low-density lipoprotein fractions was significantly lower in the bezafibrate
group than in the control group (p < 0.05).
Conclusion: Bezafibrate significantly decreased postprandial endothelial dysfunction, and elevations of both
exogenous and endogenous triglycerides in patients with metabolic syndrome, suggesting that bezafibrate may
have vascular protective effects in these patients.
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Non-fasting postprandial serum triglyceride (TG) con-
centrations have been shown to predict the risk of
cardiovascular pathology more accurately than fasting
TG concentrations, and this relationship is independent
of traditional risk factors for coronary artery disease.
[1,2] TG-rich lipoproteins (TRLs), which include chylo-
microns (CMs) assembled from TGs, dietary choles-
terol, and apolipoprotein B-48 (ApoB-48), are highly
atherogenic, [3,4] because postprandial TRL elevation
occurs in conjunction with the production of proin-
flammatory cytokines and oxidative stress, resulting in
endothelial dysfunction [5,6]. Therefore, identification
of novel therapeutic approaches to lower postprandial
concentrations of serum lipids is of great clinical
interest.
Fibrates are one of the most important classes of med-
ications currently used to treat atherogenic dyslipidemia
[7]. Bezafibrate is the only clinically available peroxisome
proliferator-activated receptor agonist that acts on all three
receptor subtypes (α, β, and δ) [8]. Bezafibrate improves
serum lipid profiles [8] insulin sensitivity 2 [9] and fasting
endothelial function [10,11]. Several studies have shown
favorable effects of fibrates on postprandial TG elevation,
but the reported effects on postprandial endothelial
dysfunction are ambiguous. Improved flow-mediated
dilation (FMD) after oral fat loading has been shown in
patients with type 2 diabetes mellitus after 12 weeks of
ciprofibrate therapy, [12] but no such benefits were
observed in healthy volunteers after 3 weeks of gemfi-
brozil therapy [13]. Only one study has examined the
effect of bezafibrate directly on postprandial lipemia
[14]. However, its effects on postprandial endothelial
dysfunction have not been investigated. The aim of this
study was to investigate the effects of bezafibrate on
postprandial TRLs and postprandial lipemia-induced
endothelial dysfunction in patients with metabolic
syndrome.Figure 1 Study design.Methods
This study was approved by the Ethics Committee of
Okayama University Graduate School of Medicine,
Dentistry, and Pharmaceutical Sciences, and written
informed consent was obtained from all participants
before beginning the protocol. This study was con-
ducted according to the principles expressed in the
Declaration of Helsinki and is registered in the UMIN
Clinical Trials Registry (UMIN000012557).
Participants and design
This was a randomized crossover study and all proce-
dures were performed at Okayama University Hospital.
After the possible consequences of the study were ex-
plained, all participants provided written informed consent
prior to screening and study enrollment. Eligible subjects
were patients diagnosed with metabolic syndrome ranging
in age from 20 to 85 years. All participants underwent
pre-study medical exams and medical history interviews.
Metabolic syndrome was diagnosed using the definition of
the International Diabetes Federation [15]. In male Asians,
central obesity is required (≥80 cm) for a diagnosis of
metabolic syndrome in addition to at least two of the fol-
lowing: blood pressure of ≥130/85 mmHg and/or current
use of antihypertensive medication; fasting plasma glucose
of ≥100 m/dl and/or current use of antidiabetic medica-
tion; TG of ≥150 mg/dl; and high-density lipoprotein
cholesterol (HDL-C) of <40 mg/dl. The study consisted
of two 4-week crossover treatment periods in which half
of the participants (chosen randomly) were adminis-
tered 400 mg/day bezafibrate orally and the other half
of the participants did not receive bezafibrate. In the sec-
ond 4-week period, the groups were reversed (Figure 1). A
“cookie test”, where subjects received a standardized
snack, was performed after the 4-week treatment period.
There was a 4-week period between the two phases during
which neither group received bezafibrate. The pre-
specified primary outcome measure was the difference
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the bezafibrate and control groups, and the secondary out-
come measure was the difference in lipid profiles after the
cookie test between the bezafibrate and control groups.
Cookie test protocol
After fasting overnight for at least 8 h, a cookie test was
performed [16]. The cookie consisted of 75 g carbohy-
drate, 28.5 g fat, and 8 g protein for a total of 592 kcal
per cookie (Saraya Corp., Osaka, Japan) [17]. Subjects
were given the amount of cookies equivalent to 30 g fat/
m2 body surface area and were instructed to ingest the
cookies with water within 20 min. The experimental
starting point began when half of the cookies had been
ingested. Venous blood samples were drawn and FMD
was measured during the fasting state before and 2, 4, 6,
and 8 h after the cookie test. The participants were
instructed not to eat anything else for 8 h after eating
the cookies. FMD was measured by a single technician
who was blinded to the study design and treatment sta-
tus of the participants.
Measurement of biochemical parameters
The following parameters were measured in the fasting
state before cookie ingestion: serum total cholesterol
(Total-C), TG, low-density lipoprotein cholesterol (LDL-C),
HDL-C, remnant lipoprotein cholesterol (RLP-C), Apo
B-48, pentraxin 3, plasma insulin, plasma glucose, and
hemoglobin A1c. These measurements were performed by
SRL Company, Ltd. (Tokyo, Japan). Homeostasis model
assessment ratio (HOMA-R) was calculated as “Fasting glu-
cose × Fasting insulin)/405”. Serum cholesterol and TG
contents of lipoprotein fractions were analyzed by high-
performance liquid chromatography performed by Skylight
Biotech (Akita, Japan), as described previously [18]. Homeo-
stasis model assessment of insulin resistance (HOMA-IR)
was calculated as fasting plasma glucose (mg/dl) × fasting
plasma insulin (μU/ml)/405. Serum total-C, TG, LDL-C,
HDL-C, RLP-C, ApoB-48, plasma glucose, plasma insulin,
and pentraxin 3 were measured 2, 4, 6, and 8 h after the
cookie test. To compare the postprandial changes in these
parameters before and after treatment for 4 weeks, AUC
was calculated using the trapezoidal method.
Measurement of FMD
FMD was measured according to the published guide-
lines for ultrasound assessment of FMD of the brachial
artery [19]. Using a 10-MHz linear-array transducer probe
(Unex Company Ltd., Nagoya, Japan), longitudinal images
of the brachial artery at baseline were recorded with a
stereotactic arm, and artery diameter was measured after
supine rest for ≥5 min. The artery diameter was measured
from clear anterior (media-adventitia) and posterior (in-
tima-media) interfaces, which were determined manually.Suprasystolic compression (50 mmHg higher than systolic
blood pressure) was performed at the right forearm for
5 min, and the artery diameter was measured continuously
from 30 s before to ≥2 min after cuff release. All measure-
ments of FMD were made by a single technician blinded
to drug allocation; the intra- and inter-observer correl-
ation coefficients were high (>0.9).
Statistical analysis
Sample size was determined on the basis of the esti-
mated FMD reported in a recent study [20]. From this
estimate, we assumed a mean improvement in postpran-
dial % FMD of 2.7% with standard deviation of 2.0% by
bezafibrate administration. To use a two-sided test for
differences between groups, a minimal sample size of 8
participants was required to detect statistical differences
in % FMD with a power of 90% and an α-type error of
5%. Results and data in the figures are expressed as
mean ± standard error (SE). Differences in lipid profiles
and endothelial function between the two groups were
compared using the Wilcoxon signed -rank test. Spear-
man correlation coefficients were used to assess relation-
ships between maximum reduction in % FMD and lipid
and glucose profiles. Values of p < 0.05 were considered
significant.
Results
Characteristics of participants during fasting
The mean age of the participants was 43 ± 10 years, and
the mean body mass index was 28.8 ± 1.2 kg/m2. All par-
ticipants were men. Table 1 shows the lipid/lipoprotein
profiles and the glycemic parameters of the participants
following each 4-week phase of control or treatment
with 400 mg/day bezafibrate. Bezafibrate treatment sig-
nificantly decreased the fasting levels of total-C, TG, RLP-
C, and ApoB-48 but did not affect the levels of LDL-C,
HDL-C, plasma glucose, insulin, hemoglobin A1c, and
pentraxin 3. No significant differences were observed in
systolic and diastolic blood pressure following bezafibrate
treatment.
Postprandial endothelial function
Figure 2 presents the comparison of postprandial endo-
thelial function, which was assessed by % FMD, between
the bezafibrate and control groups. In both groups, post-
prandial % FMD decreased significantly after the cookie
test and reached its lowest value at 4 h. The decrease in
postprandial FMD relative to the baseline was signifi-
cantly improved by bezafibrate treatment but not by the
control (−29.0 ± 5.9 vs. −42.9 ± 6.2%, p = 0.04).
Postprandial lipid and glucose parameters
Serial changes in the levels of lipids/lipoproteins, glucose,
insulin, and pentraxin 3 in postprandial samples following
Table 1 Characteristics of fasted participants after a
4-week administration of bezafibrate or control
Bezafibrate Control p
Body mass index (kg/m2) 28.8 ± 1.2 28.6 ± 1.1 0.24
Systolic blood pressure (mmHg) 127 ± 4 125 ± 4 0.34
Diastolic blood pressure (mmHg) 78 ± 3 80 ± 2 0.98
Heart rate (beats/min) 64 ± 2 65 ± 1 0.20
Laboratory data
Total-C (mg/dl) 217 ± 9 197 ± 8 0.02
LDL-C (mg/dl) 129 ± 6 135 ± 9 0.57
HDL-C (mg/dl) 46 ± 3 43 ± 3 0.22
TG (mg/dl) 135 ± 24 203 ± 35 <0.01
RLP-C (mg/dl) 5.7 ± 0.7 7.9 ± 1.3 0.02
ApoB-48 (μg/ml) 3.5 ± 0.7 6.0 ± 1.5 0.02
Glucose (mg/dl) 97 ± 3 101 ± 5 0.15
Insulin (μU/ml) 12.7 ± 4.8 8.5 ± 1.4 0.43
HOMA-IR 2.9 ± 0.2 2.1 ± 0.2 0.48
Hemoglobin A1c (%) 5.2 ± 0.3 5.3 ± 0.3 0.17
Pentraxin 3 (ng/ml) 1.5 ± 0.2 1.5 ± 0.2 0.64
Endothelial function
Brachial artery diameter (mm) 4.3 ± 0.2 4.3 ± 0.2 0.70
% FMD 6.9 ± 0.7 5.9 ± 0.7 0.04
Data are mean ± SE. Total-C, total cholesterol; LDL-C, low-density lipoprotein
cholesterol; HDL-C, high-density lipoprotein cholesterol; TGs, triglycerides;
RLP-C, remnant lipoprotein cholesterol; ApoB-48, apolipoprotein B-48; HOMA-IR,
homeostasis model assessment of insulin resistance; FMD, flow-mediated dilation.
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shown in Figure 3 and Additional file 1: Table S1. In the
control group, the postprandial levels of serum TG, RLP-C,
and ApoB-48 increased over time, peaked at 4 h, and then
decreased, and the levels of glucose and insulin increased,
peaked at 2 h, and then decreased. The levels of total-C,Figure 2 Postprandial changes in % FMD after the cookie test in the
change in % FMD (B). Data are expressed as mean ± SE. *p < 0.05 vs. contLDL-C, HDL-C, and pentraxin 3 did not change signifi-
cantly during the postprandial period in the control group.
The changes in postprandial TGs, RLP-C, and ApoB-
48 at 4 h were significantly smaller in the bezafibrate
group than in the control group (Figure 3). The incre-
mental AUCs for serum TG and RLP-C were signifi-
cantly smaller in the bezafibrate group than in the
control group (TG: 544 ± 65 vs. 1158 ± 283 mg h/dl, p =
0.02; RLP-C: 27.9 ± 3.5 vs. 72.3 ± 14.1 mg h/dl, p < 0.01),
whereas no differences in the incremental AUC for
ApoB-48 were observed (27.3 ± 4.2 vs. 33.2 ± 5.1 μg h/ml,
p = 0.31). The total AUC for total-C in the bezafibrate
group was significantly smaller than that in the control
group (1580 ± 72 vs. 1749 ± 76 mg h/dl), No differences in
the total AUC for LDL-C and HDL-C were observed be-
tween the bezafibrate and control groups (LDL-C: 1005 ±
41 vs. 1058 ± 76 mg h/dl, p = 0.52; HDL-C: 356 ± 18 vs.
328 ± 10 mg h/dl, p = 0.14). Moreover, no significant differ-
ences in the total AUC for glucose, insulin, or pentraxin 3
were observed between the bezafibrate and control groups
(glucose: 881 ± 75 vs. 898 ± 89 mg h/dl, p = 0.52; insulin:
344 ± 83 vs. 266 ± 51, p = 0.29; pentraxin 3: 11.0 ± 1.0 vs.
11.1 ± 0.9 ng h/ml, p = 0.87).
The relationships of FMD with lipid and glucose pa-
rameters at baseline and postprandially, and their corre-
sponding changes in response to the cookie test in the
bezafibrate and control groups, were evaluated (Tables 2
and 3). The associations of FMD with TRLs and glucose
parameters at baseline were mild to moderate. Change
in FMD showed mild to moderate correlations with
changes in postprandial TG, RLP-C, and ApoB-48 in
either group. Change in FMD showed almost no correla-
tions with changes in glucose, insulin, and HOMA-R.
To further examine postprandial lipid changes, chol-
esterol and TG concentrations in lipoprotein fractions
in the size range of CM, very low-density lipoproteincontrol and bezafibrate groups (A) and the relative maximum
rol group.
Figure 3 Serial postprandial changes in glucose (A), TG (B), RLP-C (C), ApoB-48 (D), LDL-C (E), and HDL-C (F) in the control and
bezafibrate groups. Data are expressed as mean ± SE. *p < 0.05 vs. control group.
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bezafibrate and control groups (Figure 4 and Additional
file 2: Table S2). The fasting TG content of the VLDL,
LDL, and HDL fractions was significantly reduced after
bezafibrate treatment (Figure 4A). The postprandial TG
content (4 h after the cookie test) of the CM, VLDL, LDL,
and HDL fractions was also reduced in the bezafibrate
group compared with the control group (Figure 4B). Fur-
thermore, the change in TG content from fasting to 4 h
was significantly reduced in the CM, VLDL, and HDL
fractions in the bezafibrate group compared with the con-
trol group (Figure 4C). Fasting cholesterol concentrations
in the LDL fractions and postprandial cholesterol concen-
trations in the CM and VLDL fractions were slightly, but
significantly, lower in the bezafibrate group than in the
control group (Additional file 2: Table S2).Discussion
This study demonstrated that bezafibrate significantly
improved postprandial endothelial dysfunction and re-
duced both exogenous and endogenous postprandial TG
levels in patients with metabolic syndrome. The poten-
tial association between the improvement in endothelial
dysfunction and the decrease in TRLs suggests that
bezafibrate may have vascular protective effects. Conse-
quently, the risk of cardiovascular disease, especially the
risk associated with postprandial TGs, may be reduced
with bezafibrate treatment.
Our results are consistent with previous studies dem-
onstrating reduced postprandial TG in response to
fibrate treatment [12,21]. Evans et al. reported that
ciprofibrate treatment for 3 months improved postpran-
dial endothelial dysfunction and postprandial TG levels
Table 2 Correlations between FMD and lipid and glucose
parameters at baseline and postprandially and changes




Baseline 4 h Change
r p r p r p
TG −0.42 0.23 −0.23 0.53 −0.51 0.13
RLP-C −0.41 0.24 −0.36 0.31 −0.54 0.10
ApoB-48 −0.23 0.53 −0.19 0.59 −0.42 0.23
Baseline 2 h Change
r p r p r p
Glucose −0.33 0.36 −0.16 0.65 −0.07 0.86
Insulin −0.31 0.39 −0.21 0.57 −0.13 0.71
HOMA-R −0.36 0.31 −0.17 0.65 −0.08 0.91
FMD, flow-mediated dilation; TG, triglyceride; RLP-C, remnant lipoprotein
cholesterol; ApoB-48, apolipoprotein B-48; HOMA-R, Homeostasis model
assessment ratio.
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tients with type 2 diabetes mellitus [12]. Rosenson et al.
reported that fenofibrate treatment for 6 weeks signifi-
cantly ameliorated postprandial hypertriglyceridemia,
oxidative stress and inflammatory response after inges-
tion of a test meal containing standardized fat (50 g/m2)
in patients with hypertriglyceridemia and the metabolic
syndrome [21]. Blood TG concentrations reflect the bal-
ance between uptake of TG into and clearance from the
circulation. The majority of TG secreted into the blood-
stream after a high-fat meal is from fat absorption via
enterocytes [22]. We demonstrated that intestinal TGs
in chylomicrons and TG in VLDLs are decreased by
bezafibrate. This is consistent with the findings of an
experimental study, which found that postprandial chy-
lomicrons and VLDLs were reduced in the plasma ofTable 3 Correlations between FMD and lipid and glucose
parameters at baseline and postprandially, and changes




Baseline 4 h Change
r p r p r p
TG −0.33 0.35 −0.21 −0.60 −0.41 0.24
RLP-C −0.39 0.27 −0.15 0.68 −0.26 0.47
ApoB-48 −0.39 0.27 −0.29 0.42 −0.37 0.29
Baseline 2 h Change
r p r p r p
Glucose −0.47 0.17 −0.51 0.13 0.004 0.99
Insulin −0.33 0.36 −0.41 0.24 0.14 0.7
HOMA-R −0.38 0.27 −0.47 0.17 0.16 0.66
FMD, flow-mediated dilation; TG, triglyceride; RLP-C, remnant lipoprotein
cholesterol; ApoB-48, apolipoprotein B-48; HOMA-R, Homeostasis model
assessment ratio.bezafibrate-treated mice [23]. CM and VLDL-sized parti-
cles have been reported to include chylomicron remnants,
suggesting that the postprandial TG-lowering effects of
bezafibrate are mainly due to decreased uptake of TG into
the circulation and increased clearance of TGs from the
bloodstream [24]. However, a formal kinetic approach is
required to confirm these findings and to evaluate the pre-
cise underlying mechanisms.
In this study, the changes in TRLs were moderately
correlated with changes in FMD, although these correla-
tions did not reach statistical significance. The sample
size (n = 10) may have been too small to detect statistical
significance, or bezafibrate may have a direct favorable
effect on vascular function. Alternatively, improvements
in vasodilation following fibrate therapy may have been
due to changes in lipoprotein profiles. Indeed, bezafibrate
can protect endothelial function in various populations
including patients with metabolic syndrome [11] or coron-
ary artery disease, [10] and we found that fasting % FMD
was significantly improved in the bezafibrate group com-
pared with the control group. Furthermore, bezafibrate in-
creases the expression of endothelial nitric oxide synthase
in cultured endothelial cells and increases nitric oxide bio-
activity [25,26]. Suppression of systemic inflammation by
peroxisome proliferator-activated receptor α activation is
an additional mechanism whereby bezafibrate may en-
hance nitric oxide synthase activity [27]. Thus, bezafibrate
treatment for 4 weeks may have preventive effects against
postprandial endothelial dysfunction. Postprandial TRL-
induced inflammation and oxidative stress, which affect
the metabolism of nitric oxide and the release of vasocon-
strictive mediators, result in endothelial dysfunction [6,28].
In our study, we evaluated the levels of pentraxin 3 as a
marker of inflammation. Pentraxin 3 is produced by vascu-
lar endothelial cells and may more directly reflect the in-
flammatory status of the vasculature [29-31]. Therefore, an
increase in pentraxin 3 after the cookie test was expected,
but no significant changes were observed both in the
control and bezafibrate groups. Therefore, further studies
are necessary to determine whether the administration of
bezafibrate limits postprandial inflammation and oxidative
stress and to evaluate the interplay between these stresses
and endothelial function.
Our finding showed that the baseline triglyceride con-
centration was much lower in the bezafibrate than in the
control group and that baseline TG was significantly cor-
related with baseline ApoB-48 concentration (r > 0.9, p <
0.01, data not shown). Baseline ApoB-48 may affect the
peak TG concentration after the cookie test, because the
assembly of CM in enterocytes depends on baseline apoB-
48 concentration. Thus, baseline TG may represent the
postprandial response.
Previous large studies reported that bezafibrate in-
creases HDL-cholesterol concentrations by over 10%
Figure 4 TG content of lipoprotein fractions in the size range of CM, VLDL, LDL, and HDL in the control and bezafibrate groups in the
fasting state (A) and 4 h after cookie ingestion (B). The change in the TG content of lipoprotein fractions in the size range of CM, VLDL, LDL,
and HDL from the fasting state to 4 h after cookie ingestion (C). Data are expressed as mean ± SE. *p < 0.05 vs. control group.
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lesterol concentration by 3 mg/dl (about 7 %), although this
difference did not reach statistical significance. The four-
week duration of bezafibrate treatment may have been too
short to significantly increase HDL-cholesterol concen-
trations. Bezafibrate has been shown to benefit patients
with atherogenic dyslipidemia. As our study population
consisted of patients with the metabolic syndrome,
it was not unexpected that the increase in HDL-
cholesterol would be less than observed in patients with
diabetes mellitus and atherogenic dyslipidemia. In con-
trast, a recent study showed that bezafibrate treatment of
patients with type 2 diabetes mellitus increased cholesterol
efflux, but had no effect on the anti-inflammatory activity
of HDL [36]. Thus, bezafibrate may have specific effects
on HDL concentrations and functions.
In clinical trials, bezafibrate has been highly effective
at reducing cardiovascular disease risk in patients with
metabolic syndrome or atherogenic dyslipidemia [32,37].
A prospective observational study found that bezafibrate
significantly improved HbA1c in dyslipidemic patients
with diabetes in Japan [35]. At present, statins are themost widely applied therapy for the treatment and pre-
vention of cardiovascular diseases related to atheroscler-
osis [38,39]. Despite the increased use of statins as a
monotherapy for elevated LDL-C, a significant residual
risk of cardiovascular disease remains for patients with
atherogenic dyslipidemia and insulin resistance, which
are typical in patients with type 2 diabetes mellitus and
metabolic syndrome. Combined bezafibrate–statin therapy
is more effective for achieving comprehensive lipid control
and reducing cardiovascular disease risk [8,37,40,41].
Our study has several limitations. First, this was a
single-blind study, and the number of participants en-
rolled was small. Therefore, some selection bias may have
occurred. Second, no widely accepted method has been
established for assessing postprandial hyperlipemia. The
oral cookie test—with a defined quantity of fat per body
surface area—may be a reliable method for detecting post-
prandial metabolic disturbances. The oral cookie test used
in this study contains a greater content of carbohydrates
than fat loading meals. These high-carbohydrate meals
have a greater effect on glycemic parameters, including
glucose and insulin concentrations, than high-fat meals.
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thelial function and the effects of bezafibrate. Finally,
because patients were only treated with bezafibrate for
4 weeks, we were not able to evaluate the long-term
effects of bezafibrate on postprandial lipid dynamics.
Conclusions
In this crossover study, we demonstrated that bezafibrate
was effective at reducing postprandial TRL elevation and
the accompanying induction of postprandial endothelial
dysfunction in patients with metabolic syndrome. Beza-
fibrate may be useful in reducing future cardiovascular
disease by ameliorating postprandial endothelial dys-
function in these patients.
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Additional file 1: Table S1. Postprandial changes in lipid profiles and
glycemic parameters in the bezafibrate and control groups.
Additional file 2: Table S2. TG and cholesterol concentrations in
lipoprotein fractions in the chylomicron, VLDL, LDL, and HDL fractions.
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